Pantoprazol Cinfa (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Cinfa, is a proton pump inhibitor presented as a unknown strength/unknown form for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Pantoprazol Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Cinfa is a proton pump inhibitor that acts on the gastric acid secretion pathway to manage several acid‑related conditions. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: accelerates healing of erosive lesions in the oesophagus. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the syndrome.

Pantoprazol Cinfa may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache - Diarrhoea - Nausea - Abdominal pain - Flatulence - Constipation

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Clostridioides difficile‑associated colitis - Low magnesium levels (hypomagnesemia) - Acute interstitial nephritis - Liver enzyme elevation - Fracture risk with long‑term use

Before prescribing Pantoprazol Cinfa, clinicians should consider several safety aspects. - Assess renal function: adjust dose in severe renal impairment. - Monitor magnesium: prolonged therapy may lower serum magnesium. - Evaluate bone health: long‑term use is associated with increased fracture risk. - Review concomitant medications: potential for altered absorption of drugs requiring acidic pH. - Pregnancy and lactation: use only if clearly needed. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Antifungal azoles (ketoconazole, itraconazole): reduced absorption due to increased gastric pH. - Atorvastatin: increased plasma concentrations, raising risk of myopathy.

Moderate Interactions (Monitor Closely): - Warfarin: possible enhancement of anticoagulant effect. - Digoxin: altered absorption may change serum levels. - Methotrexate: reduced renal clearance can increase toxicity. - Clopidogrel: diminished activation may lower antiplatelet efficacy.